Search Results - "de las Penas, R"

SEOM clinical guideline for treatment of cancer pain (2017) by Jara, C., del Barco, S., Grávalos, C., Hoyos, S., Hernández, B., Muñoz, M., Quintanar, T., Meana, J. A., Rodriguez, C., de las Peñas, R.

“…Pain is a highly prevalent symptom in patients with cancer. Despite therapeutic advances and well-accepted treatment guidelines, a percentage of patients with…”
Get full text

Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial by ALBEROLA, V, CAMPS, C, GONZALEZ-LARRIBA, J. L, DIZ, P, CARDENAL, F, ARTAL, A, CARRATO, A, MORALES, S, SANCHEZ, J. J, DE LAS PENAS, R, FELIP, E, LOPEZ-VIVANCO, G, PROVENCIO, M, ISLA, D, ROSELL, R, VADELL, C, BOVER, I, RUIZ-CASADO, A, AZAGRA, P, JIMENEZ, U

“…To compare the survival benefit obtained with cisplatin plus gemcitabine, a cisplatin-based triplet, and nonplatinum sequential doublets in advanced…”
Get full text

SEOM clinical guidelines on nutrition in cancer patients (2018) by de las Peñas, R., Majem, M., Perez-Altozano, J., Virizuela, J. A., Cancer, E., Diz, P., Donnay, O., Hurtado, A., Jimenez-Fonseca, P., Ocon, M. J.

“…Nutritional deficiency is a common medical problem that affects 15–40% of cancer patients. It negatively impacts their quality of life and can compromise…”
Get full text

SEOM clinical guidelines on cardiovascular toxicity (2018) by Virizuela, J. A., García, A. M., de las Peñas, R., Santaballa, A., Andrés, R., Beato, C., de la Cruz, S., Gavilá, J., González-Santiago, S., Fernández, T. L.

“…One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor’s prognosis. Cardiotoxicity…”
Get full text

SEOM guidelines on hydroelectrolytic disorders by De las Peñas, R., Escobar, Y., Henao, F., Blasco, A., Rodríguez, C. A.

“…Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions…”
Get full text

Replied to “Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)” by Virizuela, J. A., Garcia, A. Martin, de las Peñas, R., Santaballa, A., Andrés, R., Beato, C., de la Cruz, S., Gavilá, J., González-Santiago, S., Fernández, T. López

Get full text

SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016) by de las Peñas, R., Blasco, A., De Castro, J., Escobar, Y., García-Campelo, R., Gúrpide, A., Lopez-Lopez, R., Majem, M., Rodríguez, C. A., Virizuela, J. A.

“…Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects of chemotherapy for cancer patients. It can cause severe discomfort and…”
Get full text

Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology by Goday, A., Barneto, I., García-Almeida, J. M., Blasco, A., Lecube, A., Grávalos, C., Martínez de Icaya, P., de las Peñas, R., Monereo, S., Vázquez, L., Palacio, J. E., Pérez-Segura, P.

“…In the last few years, many prospective studies have demonstrated a clear association between obesity and cancers of the colon and rectum, breast in…”
Get full text

Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology by Pérez-Segura, P., Palacio, J. E., Vázquez, L., Monereo, S., de las Peñas, R., de Icaya, P. Martínez, Grávalos, C., Lecube, A., Blasco, A., García-Almeida, J. M., Barneto, I., Goday, A.

“…The relationship between obesity and cancer is clear and is present at all times during course of the disease. The importance of obesity in increasing the risk…”
Get full text

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients by de las Peñas, R., Sanchez-Ronco, M., Alberola, V., Taron, M., Camps, C., Garcia-Carbonero, R., Massuti, B., Queralt, C., Botia, M., Garcia-Gomez, R., Isla, D., Cobo, M., Santarpia, M., Cecere, F., Mendez, P., Sanchez, J.J., Rosell, R.

“…Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated non-small-cell lung cancer (NSCLC) patients. We…”
Get full text

A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma by Gately, L., Mesía, C., Sepúlveda, J. M., del Barco, S., Pineda, E., Gironés, R., Fuster, J., Hong, W., Dumas, M., Gill, S., Navarro, L. M., Herrero, A., Dowling, A., de las Peñas, R., Vaz, M. A., Alonso, M., Lwin, Z., Harrup, R., Peralta, S., Long, A., Perez-Segura, P., Ahern, E., Garate, C. O., Wong, M., Campbell, R., Cuff, K., Jennens, R., Gallego, O., Underhill, C., Martinez-Garcia, M., Covela, M., Cooper, A., Brown, S., Rosenthal, M., Torres, J., Collins, I. M., Gibbs, P., Balana, C.

“…Purpose The optimal duration of post-radiation temozolomide in newly diagnosed glioblastoma remains unclear, with no published phase III randomised trials…”
Get full text

Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM) by Gately, Lucy, Mesía, C., Sepúlveda, J. M., del Barco, S., Pineda, E., Gironés, R., Fuster, J., Dumas, M., Gill, S., Navarro, L. M., Herrero, A., Dowling, A., de las Peñas, R., Vaz, M. A., Alonso, M., Lwin, Z., Harrup, R., Peralta, S., Long, A., Perez-Segura, P., Ahern, E., Garate, C. O., Wong, M., Campbell, R., Cuff, K., Jennens, R., Gallego, O., Underhill, C., Martinez-Garcia, M., Covela, M., Cooper, A., Brown, S., Rosenthal, M., Torres, J., Collins, I. M., Gibbs, P., Balana, C.

“…Purpose The impact of age on optimal management of glioblastoma remains unclear. A recent combined analysis of two randomised trials, GEINO14-01 and EX-TEM,…”
Get full text

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer by Provencio, M., Camps, C., Cobo, M., De las Peñas, R., Massuti, B., Blanco, R., Alberola, V., Jimenez, U., Delgado, J. R., Cardenal, F., Tarón, M., Ramírez, J. L., Sanchez, A., Rosell, R.

“…Purpose New therapeutic approaches are being developed based on findings that several genetic abnormalities underlying non-small-cell lung cancer (NSCLC) can…”
Get full text

Neoadjuvant Treatment Before Radiation for Patients With Glioblastoma (GBM) Only Biopsied: A Multicentric Phase 2 Randomized Trial by Villa, S, Balana, C, Conde, A, Lucas, A, Rodriguez, V, Zurita, M, De Las Penas, R, Gil, M, Sepulveda, J, Luque, R

Get full text

Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients by Balaña, C., Estival, A., Teruel, I., Hardy-Werbin, M., Sepulveda, J., Pineda, E., Martinez-García, M., Gallego, O., Luque, R., Gil-Gil, M., Mesia, C., Del Barco, S., Herrero, A., Berrocal, A., Perez-Segura, P., De las Penas, R., Marruecos, J., Fuentes, R., Reynes, G., Velarde, J. M., Cardona, A., Verger, E., Panciroli, C., Villà, S.

“…Purpose We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected…”
Get full text

SEOM clinical guidelines for anaemia treatment in cancer patients (2020) by Escobar Álvarez, Y., de las Peñas Bataller, R., Perez Altozano, J., Ros Martínez, S., Sabino Álvarez, A., Blasco Cordellat, A., Brozos Vázquez, E., Corral Jaime, J., García Escobar, I., Beato Zambrano, C.

“…Anaemia is defined by the presence of haemoglobin (Hb) levels < 13 g/dL in men and 12 g/dL in women. Up to 39% of cancer patients present it at the time of…”
Get full text

Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS) by Buesa, J.M, Garcia del Muro, J, Cruz, J, Montalar, J, Escudero, P, Martin, J, Maurel, J, Lopez-Pousa, A, de las Penas, R, Casado, A

“…Background. To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m(2) every 4 weeks in patients…”
Get full text

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma by Gately, L., Mesía, C., Sepúlveda, J. M., del Barco, S., Pineda, E., Gironés, R., Fuster, J., Hong, W., Dumas, M., Gill, S., Navarro, L. M., Herrero, A., Dowling, A., de las Peñas, R., Vaz, M. A., Alonso, M., Lwin, Z., Harrup, R., Peralta, S., Long, A., Perez-Segura, P., Ahern, E., Garate, C. O., Wong, M., Campbell, R., Cuff, K., Jennens, R., Gallego, O., Underhill, C., Martinez-Garcia, M., Covela, M., Cooper, A., Brown, S., Rosenthal, M., Torres, J., Collins, I. M., Gibbs, P., Balana, C.

Get full text

Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis by BARRAJON, E, DE LAS PENAS, R

“…The goals of this work were to compare the relative efficacy of ondansetron, granisetron and tropisetron in a randomised double blind crossover trial,…”
Get full text

Clinical utility of complex multi-platform profiling in metastatic cancer patients by Garcia Foncillas, J., Aftimos, P.G., Barthelemy, P., Bellmunt, J., Berchem, G., Camps, C., de las Peñas, R., Finzel, A., Hervonen, J.P., Joensuu, T., Kong, A., Mackay, J., Mikropoulos, C., Mokbel, K., Mouysset, J.-L., Perren, T.-J., Guitti, G., Laes, J.-F.

Get full text